Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli

Clinical and Vaccine Immunology

Volumn 20, Issue 11, 2013, Pages 1764-1770

  El Kamary, Samer S ^a   Cohen, Mitchell B ^b   Bourgeois, A Louis ^c   Van De Verg, Lillian ^c   Bauers, Nicole ^c   Reymann, Mardi ^a   Pasetti, Marcela F ^a   Chen, Wilbur H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c PATH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; RECOMBINANT DOUBLE MUTANT HEAT LABILE TOXIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; BACKACHE; BACTERIUM IDENTIFICATION; BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROTOXIGENIC ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; NAUSEA; NECK PAIN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; VACCINATION; VACCINATION REACTION; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY-PRODUCING CELLS; BACTERIAL TOXINS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENTEROTOXIGENIC ESCHERICHIA COLI; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FECES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84886731020     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00464-13     Document Type: Article

References (32)

1. Steffen R, Castelli F, Dieter Nothdurft H, Rombo L, Jane Zuckerman N. 2005. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J. Travel Med. 12:102-107.
2. Wenneras C, Erling V. 2004. Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world. J. Health Popul. Nutr. 22:370-382.
3. Isidean SD, Riddle MS, Savarino SJ, Porter CK. 2011. A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine 29:6167-6178.
4. Black RE. 1990. Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev. Infect. Dis. 12(Suppl 1):S73-S79.
5. Black RE. 1993. Epidemiology of diarrhoeal disease: implications for control by vaccines. Vaccine 11:100-106.
6. Steffen R, Tornieporth N, Clemens SA, Chatterjee S, Cavalcanti AM, Collard F, De Clercq N, DuPont HL, von Sonnenburg F. 2004. Epidemiology of travelers' diarrhea: details of a global survey. J. Travel Med. 11:231-237.
7. Walker RI, Steele D, Aguado T. 2007. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine 25:2545-2566.
8. Allen KP, Randolph MM, Fleckenstein JM. 2006. Importance of heat-labile enterotoxin in colonization of the adult mouse small intestine by human enterotoxigenic Escherichia coli strains. Infect. Immun. 74:869-875.
9. Berberov EM, Zhou Y, Francis DH, Scott MA, Kachman SD, Moxley RA. 2004. Relative importance of heat-labile enterotoxin in the causation of severe diarrheal disease in the gnotobiotic piglet model by a strain of enterotoxigenic Escherichia coli that produces multiple enterotoxins. Infect. Immun. 72:3914-3924.
10. Glenn GM, Francis DH, Danielsen EM. 2009. Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines. Infect. Immun. 77:5206-5215.
11. Ahren CM, Svennerholm AM. 1982. Synergistic protective effect of antibodies against Escherichia coli enterotoxin and colonization factor antigens. Infect. Immun. 38:74-79.
12. Zhang W, Sack DA. 2012. Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans. Expert Rev. Vaccines 11:677-694.
13. Ellingsworth L. 2011. Transcutaneous immunization and the travelers' diarrhea vaccine system: a phase III pivotal efficacy study. Abstr. 6th Int. Conf. Vaccines Enteric Dis. 2011, Cannes, France, 14 to 16 September 2011.
14. da Hora VP, Conceicao FR, Dellagostin OA, Doolan DL. 2011. Nontoxic derivatives of LT as potent adjuvants. Vaccine 29:1538-1544.
15. Freytag LC, Clements JD. 2005. Mucosal adjuvants. Vaccine 23:1804-1813.
16. Dickinson BL, Clements JD. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617-1623.
17. Lycke N, Tsuji T, Holmgren J. 1992. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:2277-2281.
18. Cheng E, Cardenas-Freytag L, Clements JD. 1999. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18:38-49.
19. Oplinger M, Baqar S, Trofa A, Clements J, Gibbs P, Pazzaglia G, Bourgeois A, Scott DA. 1997. Safety and immunogenicity in volunteers of a new candidate oral mucosal adjuvant, LT(R192G), abstr G-10, p 193. Prog. Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
20. Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. 2001. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69:3581-3590.
21. Tribble D, Baqar S, Thompson S. 2008. Development of a human vaccine, p 429-444. In Nachamkin ISCM, Blaser MJ (ed), Campylobacter, 3rd ed. ASM Press, Washington, DC.
22. Levine MM, Kaper JB, Black RE, Clements ML. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:510-550.
23. Norton EB, Lawson LB, Freytag LC, Clements JD. 2011. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin. Vaccine Immunol. 18:546-551.
24. Summerton NA, Welch RW, Bondoc L, Yang HH, Pleune B, Ramachandran N, Harris AM, Bland D, Jackson WJ, Park S, Clements JD, Nabors GS. 2010. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole-cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28:1404-1411.
25. Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. 2004. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine 22:4385-4389.
26. Baudner BC, Giudice GD. 2010. Determining the activity of mucosal adjuvants. Methods Mol. Biol. 626:261-285.
27. Baqar S, Nour El Din AA, Scott DA, Bourgeois AL, Mourad AS, Kleinosky MT, Oplinger MJ, Murphy JR. 1997. Standardization of measurement of immunoglobulin-secreting cells in human peripheral circulation. Clin. Diagn. Lab. Immunol. 4:375-379.
28. Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm AM. 2013. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant. Vaccine 31:2457-2464.
29. Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, Herranz M, Saldinger PF, Corthesy-Theulaz I, Losonsky G, Nichols R, Simon J, Stolte M, Ackerman S, Monath TP, Blum AL. 1999. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116:804-812.
30. Banerjee S, Medina-Fatimi A, Nichols R, Tendler D, Michetti M, Simon J, Kelly CP, Monath TP, Michetti P. 2002. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 51:634-640.
31. Leach S, Clements JD, Kaim J, Lundgren A. 2012. The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens. PLoS One 7:e51718. doi:10.1371/journal.pone.0051718.
32. Sjokvist Ottsjo L, Flach CF, Clements J, Holmgren J, Raghavan S. 2013. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect. Immun. 81:1532-1540.